BioCentury | Feb 29, 2020
Product Development

CRISPR-based diagnostics are poised to make an early debut amid COVID-19 outbreak

CRISPR could see its first direct application to human health much earlier than expected as the COVID-19 outbreak accelerates development timelines for CRISPR-based diagnostics. Diagnostic testing for COVID-19 is currently conducted with real-time PCR tests...
BioCentury | Sep 10, 2018
Distillery Techniques

Drug delivery

TECHNOLOGY: Nanoparticles Nanoparticles bound to red blood cells (RBCs) could be used to deliver drugs to the vasculature of specific organs. The method involves mixing bare nanogels with ex vivo RBCs to enable RBC-nanoparticle binding,...
BioCentury | Jun 20, 2018
Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy A four-compound cocktail could enhance the efficiency of CRISPR-based editing in pluripotent stem cells. The method involves CRISPR-based editing in pluripotent stem cells with systems based on CRISPR from Prevotella and Francisella...
BioCentury | Mar 31, 2017
Targets & Mechanisms

Cells on the rise

...Ltd. 1181 XPA DNA damage recognition and repair factor (XPA); replication protein A1 (RPA1); RPA2; RPA3...
BioCentury | Jan 20, 2017
Company News

PharmAthene, Altimmune deal

PharmAthene and Altimmune will merge into a publicly traded immunotherapeutics company based in Gaithersburg. The newco will retain Altimmune’s name and trade on NYSE MKT under the ticker ALT. Altimmune shareholders will own 58.2% of...
BioCentury | Aug 22, 2016
Clinical News

Px563L: Phase Ia data

A double-blind, placebo-controlled, U.S. Phase Ia trial in about 54 healthy volunteers showed that 2 doses of 10 or 80 ug intramuscular Px563L given 28 days apart led to a TNA NF50 value of >=0.56...
BioCentury | Aug 8, 2016
Clinical News

Pfenex regains rights to Lucentis biosimilar, reports data

Pfenex Inc. (NYSE-M:PFNX) regained worldwide rights to PF582 and said the biosimilar of Lucentis ranibizumab met the primary endpoint of demonstrating similar safety and tolerability to its reference product in a Phase I/II study to...
BioCentury | Aug 8, 2016
Company News

Altimmune, U.S. Department of Health and Human Services infectious news

HHS’s Biomedical Advanced Research and Development Authority (BARDA) awarded Altimmune a five-year contract worth up to $120.2 million to develop its anthrax vaccine candidate NasoShield . Altimmune will receive $14.3 million to fund a Phase I...
BioCentury | Aug 1, 2016
Financial News

BARDA awards Altimmune anthrax contract

Altimmune Inc. (Gaithersburg, Md.) said HHS's Biomedical Advanced Research and Development Authority (BARDA) awarded it a contract for up to $120.2 million to fund clinical development of anthrax vaccine candidate NasoShield (formerly AdVAV anthrax vaccine...
BioCentury | Aug 24, 2015
Company News

Pfenex, U.S. Department of Health and Human Services infectious news

Pfenex said HHS’s Biomedical Advanced Research and Development Authority (BARDA) awarded the company a five-year contract with a total potential value of $143.5 million to develop Px563L , a recombinant protective antigen (rPA) anthrax vaccine . The...
Items per page:
1 - 10 of 158